How Can Contingent Valuation Inform the Bioethics Debate? Evidence from a Survey on Hereditary Cancers in France

Abstract : BRCA1/2 carriers have a higher risk of developing breast and ovarian cancer at a younger age. Preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND) are two of the few options available to avoid transmitting the mutation. To inform the bioethics debate about authorization, a contingent valuation survey elicited preferences regarding access to PGD and PND from a sample of 460 unaffected by cancer BRCA1/2 carriers (GENEPSO cohort). We find that the respondents can be classified into three groups: one opposed to PGD/PND (28.3%), one strongly in favour of PGD/PND (45.8%), and one in an intermediate position (25.9%). We look for the determinants of these preferences, especially of the willingness to pay for PGD/PND. Overall, we find that BRCA1/2 carriers support access to PGD/PND, which has implications for recommendations to decision-makers.
Type de document :
Article dans une revue
Revue Economique, 2017, 68 (3), pp.379--404. 〈10.3917/reco.683.0379〉
Liste complète des métadonnées

https://hal-amu.archives-ouvertes.fr/hal-01589998
Contributeur : Elisabeth Lhuillier <>
Soumis le : mardi 19 septembre 2017 - 11:59:07
Dernière modification le : jeudi 1 février 2018 - 17:38:37

Identifiants

Citation

Christel Protière, Olivier Chanel, Emmanuelle Mouret-Fourme, Claire Julian-Reynier, Catherine Noguès, et al.. How Can Contingent Valuation Inform the Bioethics Debate? Evidence from a Survey on Hereditary Cancers in France. Revue Economique, 2017, 68 (3), pp.379--404. 〈10.3917/reco.683.0379〉. 〈hal-01589998〉

Partager

Métriques

Consultations de la notice

159